ChicagoFit
Explorer
A systematic review and meta-analysis from 2026 covering more than 21,000 patients.
This study, which appeared in Renal Failure, gives a thorough overview of how well GLP-1 works and how safe it is: Meta-analysis study
Main favorable results:
1. Among people with kidney disease, GLP-1s lowered the chance of serious kidney events by 16%;
2. GLP-1s brought down albuminuria (protein escaping from the kidney into urine), an early indicator of kidney strain;
3. GLP-1s cut major heart and stroke events by 16%;
4. GLP-1s decreased "renal sinus fat" (fat surrounding the kidneys), which lightens the burden on the heart;
5. GLP-1s lowered all-cause mortality by 17%;
6. GLP-1s decreased systemic inflammation, shielding the heart, brain, and kidneys at the same time.
Main unfavorable results:
1. GLP-1s temporarily raised nausea four-fold;
2. GLP-1s temporarily raised vomiting or diarrhea three-fold.
This study, which appeared in Renal Failure, gives a thorough overview of how well GLP-1 works and how safe it is: Meta-analysis study
Main favorable results:
1. Among people with kidney disease, GLP-1s lowered the chance of serious kidney events by 16%;
2. GLP-1s brought down albuminuria (protein escaping from the kidney into urine), an early indicator of kidney strain;
3. GLP-1s cut major heart and stroke events by 16%;
4. GLP-1s decreased "renal sinus fat" (fat surrounding the kidneys), which lightens the burden on the heart;
5. GLP-1s lowered all-cause mortality by 17%;
6. GLP-1s decreased systemic inflammation, shielding the heart, brain, and kidneys at the same time.
Main unfavorable results:
1. GLP-1s temporarily raised nausea four-fold;
2. GLP-1s temporarily raised vomiting or diarrhea three-fold.